生物材料技术研究商Auxilium Health完成340万美元种子轮融资，以推进Aer™生物材料平台-动脉网

Auxilium Health Closes Oversubscribed $3.4 Million Seed Round to Advance Its Aer™ Biomaterial Platform

CISION 等信源发布 2026-07-14 22:00



可切换为仅中文







CLEVELAND

克利夫兰

，

July 14, 2026

2026年7月14日

/PRNewswire/ -- Auxilium Health today announced the close of an oversubscribed $3.4 million seed round, a year after closing its pre-seed, to advance its Aer™ biomaterial platform toward FDA clearance and first-in-human studies.

/美通社/ -- Auxilium Health 今日宣布，在完成种子前轮融资一年后，已成功关闭一轮超额认购的340万美元种子轮融资，以推动其Aer™生物材料平台获得美国食品药品监督管理局（FDA）批准并开展首次人体研究。

Backed by returning and new regional and strategic investors, the round more than doubles the company's prior raise and reflects growing conviction in both the technology and the progress behind it.

在有老股东和新加入的区域及战略投资者支持下，本轮融资额超过公司此前融资总额的两倍，反映出市场对其技术及其背后进展的信心日益增强。

继续阅读

Auxilium Health Closes Oversubscribed $3.4 Million Seed Round to Advance Its Aer™ Biomaterial Platform

Auxilium Health 完成超额认购的 340 万美元种子轮融资，以推进其 Aer™ 生物材料平台的发展

Post this

发布此内容

For nearly four decades, biomaterials have tried to win what surgeons and scientists call the 'race for the surface,' the contest between a patient's healing cells and bacteria to colonize a material first, by killing bacteria after they arrive.

近四十年来，生物材料一直试图通过杀灭到达后的细菌，来赢得外科医生和科学家所称的“表面争夺战”——即患者愈合细胞与细菌竞相率先定植于材料表面的竞争。

Auxilium takes a different approach. Its Aer™ platform is an engineered matrix-like product that mimics the body's own extracellular matrix, built to win that race structurally by resisting bacterial attachment while welcoming regenerative cells, all without relying on antibiotics.

Auxilium 采取了一种不同的方法。其 Aer™ 平台是一种工程化的类基质产品，模拟人体自身的细胞外基质，旨在通过抵抗细菌附着同时欢迎再生细胞，从而在结构上赢得这场竞争，而这一切都不依赖抗生素。

The new capital will advance the company's lead product toward FDA clearance and into first-in-human use while deepening the team and the research behind it. Over the last year, Auxilium's full-time team has doubled, attracting top researchers and scientists to relocate to Cleveland to join the mission..

新资本将推动公司的领先产品获得美国食品药品监督管理局（FDA）批准并进入首次人体应用阶段，同时壮大团队并加强相关研究。在过去一年中，Auxilium 的全职团队规模扩大了一倍，吸引了顶尖研究人员和科学家迁至克利夫兰，加入这一使命。

'Last year, the question was whether the science was real. This year, it's how fast we can get it to patients,' said Isaiah Kaiser, PhD, Founder and CEO of Auxilium Health. 'We're grateful to our investors and partners who believe in the science and the team behind what we're building. Their confidence lets us move with the urgency this problem deserves.'.

“去年，人们质疑的是这项科学是否真实可靠。今年，问题在于我们能否尽快将其应用于患者。”Auxilium Health 的创始人兼首席执行官以赛亚·凯撒博士表示。“我们感谢那些相信我们的科学以及背后团队的投资者和合作伙伴。他们的信心让我们能够以这一问题所亟需的紧迫感迅速推进。”

About Auxilium Health

关于 Auxilium Health

Auxilium Health develops a new class of bioaerogels that reduce the risk of bacterial colonization and guide tissue regeneration. Its Aer™ platform spans wound repair, bone regeneration, and localized delivery, with a lead product advancing toward FDA clearance and clinical studies. Headquartered at the Cleveland Clinic's Global Innovation Center, the company is supported by the National Science Foundation, the Ohio Department of Development, and the Polymer Industry Cluster..

Auxilium Health 开发出一类新型生物气凝胶，可降低细菌定植风险并引导组织再生。其 Aer™ 平台涵盖伤口修复、骨再生和局部递送领域，其中一款主导产品正朝着获得美国食品药品监督管理局（FDA）许可和开展临床研究的方向推进。公司总部位于克利夫兰诊所全球创新中心，并获得美国国家科学基金会、俄亥俄州发展部以及聚合物产业集群的支持。

Regeneration begins at the surface.

再生始于表面。

Media Contact

媒体联系人

Lindsey Dinneen

林赛·迪宁

Director of Marketing & Engagement

营销与参与总监

Project Medtech

Medtech 项目

[email protected]

Company Website: